blindness and tirzepatide Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Tirzepatide vs. Semaglutide for Weight

It slows gastric emptying, changes appetite signaling, and may influence the gut microbiome

530 Wherrett, D

Healthcare providers should engage patients in shared decision-making regarding treatment duration, establishing clear goals at treatment initiation and regularly reassessing the need for continued therapy

Mechanistically, tirzepatide + 5-amino-1MQ should outperform semaglutide monotherapy, but individual response variability and lack of head-to-head data prevent definitive claims

Rarely, some patients may experience sustained weight gain due to combined biological and lifestyle factors

The risks of BPC-157 are listed below